ABCL Investor Relations (IR)

• AbCellera Biologics Inc. investor relations →
  investors.abcellera.com
• Latest results release →
  Q2 2026, published Aug 5, 2026
• SEC filings on EDGAR →
  10-K, 10-Q and 8-K filing history

• Q2 2026 reported Aug 5, 2026

  Revenue $4M · EPS −$0.18

  Press release for Q2 2026 →
• Q1 2026 reported May 11, 2026

  Revenue $8M · EPS −$0.14

  Press release for Q1 2026 →
• Q4 2025 reported Feb 24, 2026

  Revenue $45M · EPS −$0.03

  Press release for Q4 2025 →
• Q3 2025 reported Nov 6, 2025

  Revenue $9M · EPS −$0.19

  Press release for Q3 2025 →

All ABCL earnings →

R40 does not score AbCellera Biologics Inc. on its latest reported quarter — capital expenditure and cash flow are too large relative to revenue for the combined score to be meaningful.